Dan Hartman

Dan Hartman

Director, Integrated Development

Dr. Dan Hartman leads a team that provides technical expertise in product development to other foundation teams and their partners. He joined the foundation in 2012 in his current role and served simultaneously as interim director of the Malaria team from 2016 to 2018.

Dan has extensive management and pharmaceutical experience. Before joining the foundation, he served for four years as president and CEO of Great Lakes Drug Development, a consulting company providing strategic and operational support for early drug development projects. Previously, he served as senior vice president of product development at deCODE genetics, executive director of Pfizer Global Research and Development, and vice president of global clinical development at Esperion Therapeutics, and he held clinical research positions at Eli Lilly & Company. He has also provided consultation to the biopharmaceutical venture capital community and serves as a member/advisor on several nonprofit boards.

Dan served as a member of the National Institutes of Health’s National Center for Advancing Translational Sciences and Cures Acceleration Network advisory board from 2016 to 2019 and was president of the American Society for Clinical Pharmacology & Therapeutics. He has received numerous awards, including Inventor of the Year from the Intellectual Property Owners Association.

He received his bachelor’s degree from Calvin College and his medical degree from Wayne State University. He trained in internal medicine and completed a fellowship in pulmonary medicine at Indiana University, where he also served as chief medical resident.

More about the foundation

Our story

Learn about the origins of the foundation and the values that drive our work.

Our work

Learn about where we work around the globe and the programs we've created to address urgent issues in global health, global development, and education.


Read the latest stories, research, and news from across the foundation and subscribe to our weekly newsletter, The Optimist.